Jove
Visualize
Contact Us

Related Concept Videos

Drug Control Governance: Regulatory Bodies and Their Impact01:03

Drug Control Governance: Regulatory Bodies and Their Impact

Drug control governance involves the oversight and regulation of pharmaceuticals to ensure their safety and efficacy while preventing illegal drug use and trafficking. Regulatory bodies, including the US Food and Drug Administration (FDA) and the European Union's European Medicines Agency (EMA), play a central role in this process. These agencies evaluate the safety and efficacy of drugs before they can be marketed. They fund clinical trials and assess the benefits and risks associated with a...
Drug Toxicity: Risk factors01:24

Drug Toxicity: Risk factors

Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
Drug Classes and Categories01:25

Drug Classes and Categories

Drugs can be classified according to their chemical composition or their intended therapeutic application. For instance, anti-infective agents that possess the ability to eliminate pathogens or suppress their growth and reproduction can be grouped based on the organisms they target or their chemical structure. Furthermore, drugs can be divided into prescription, nonprescription, or controlled substances. Prescription medications, such as antibiotics, require oversight from a licensed healthcare...
Drug Abuse and Addiction: Pharmacological Phenomena01:15

Drug Abuse and Addiction: Pharmacological Phenomena

Drug dependence, abuse, and addiction are complex phenomena that can precipitate various abnormal states. Physical dependence refers to a state of pharmacological adaptation to a drug. This adaptation often results in tolerance—a reduced response to the drug after repeated administrations. When the drug use is abruptly stopped, withdrawal symptoms occur due to the body's need to readjust from the pharmacologically induced imbalance. However, tolerance and withdrawal symptoms do not necessarily...
Drug Nomenclature01:17

Drug Nomenclature

During the development of a new pharmaceutical, the manufacturer initially assigns a code name to the drug. Once approved, the drug receives a United States Adopted Name (USAN)—a generic, nonproprietary designation. Upon being listed in the United States Pharmacopeia, this nonproprietary name becomes the drug's official name. Additionally, the manufacturer assigns a proprietary name or trademark, which serves as the brand name under which the drug is marketed. It is worth noting that the same...
Prescription, Nonprescription and Orphan Drugs01:02

Prescription, Nonprescription and Orphan Drugs

Prescription drugs require a prescription from a medical practitioner and can only be obtained from a pharmacy. They have many applications, including treating pain, anxiety, and hypertension.
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Artelon Graft Augmentation in Revision Anterior Cruciate Ligament Reconstruction: Surgical Technique Guide.

Journal of orthopaedic case reports·2026
Same author

Enhancement of a nuclear factor of activated T cells (NFAT) reporter for the study of G protein-coupled receptors.

Communications biology·2026
Same author

Safety of intravenous pantoprazole sodium in paediatric patients aged 1 year to <2 years: a real-world retrospective cohort study in the USA.

BMJ paediatrics open·2026
Same author

Green space, blue space and psychological distress in regional Australia: Cross-sectional and longitudinal analyses.

Environmental research·2025
Same author

From Combat to Search and Rescue: The Modern Air Force Pararescue Medical Experience.

Military medicine·2025
Same author

The revised risk analysis index outperforms the 5-factor modified frailty index in predicting postoperative morbidity after pilon fracture fixation.

Journal of orthopaedics·2025
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jul 15, 2026

High-throughput and Comprehensive Drug Surveillance Using Multisegment Injection-Capillary Electrophoresis-Mass Spectrometry
10:17

High-throughput and Comprehensive Drug Surveillance Using Multisegment Injection-Capillary Electrophoresis-Mass Spectrometry

Published on: April 23, 2019

Illegal drug-attributable morbidity in Canada 2002.

Svetlana Popova1, Jürgen Rehm, Jayadeep Patra

  • 1Centre for Addiction and Mental Health, Toronto, Ontario, Canada. lana_popova@camh.net

Drug and Alcohol Review
|April 25, 2007
PubMed
Summary

Illegal drug use significantly impacts Canada's health burden, causing over 61,000 hospital diagnoses and millions of treatment days in 2002. This burden has notably increased since 1992.

More Related Videos

Tracking Drug-induced Changes in Receptor Post-internalization Trafficking by Colocalizational Analysis
07:48

Tracking Drug-induced Changes in Receptor Post-internalization Trafficking by Colocalizational Analysis

Published on: July 3, 2015

Brain Morphology of Cannabis Users With or Without Psychosis: A Pilot MRI Study
07:30

Brain Morphology of Cannabis Users With or Without Psychosis: A Pilot MRI Study

Published on: August 18, 2020

Related Experiment Videos

Last Updated: Jul 15, 2026

High-throughput and Comprehensive Drug Surveillance Using Multisegment Injection-Capillary Electrophoresis-Mass Spectrometry
10:17

High-throughput and Comprehensive Drug Surveillance Using Multisegment Injection-Capillary Electrophoresis-Mass Spectrometry

Published on: April 23, 2019

Tracking Drug-induced Changes in Receptor Post-internalization Trafficking by Colocalizational Analysis
07:48

Tracking Drug-induced Changes in Receptor Post-internalization Trafficking by Colocalizational Analysis

Published on: July 3, 2015

Brain Morphology of Cannabis Users With or Without Psychosis: A Pilot MRI Study
07:30

Brain Morphology of Cannabis Users With or Without Psychosis: A Pilot MRI Study

Published on: August 18, 2020

Area of Science:

  • Public Health
  • Epidemiology
  • Substance Abuse Research

Background:

  • Illegal drug use is a significant behavioral risk factor contributing to the morbidity burden in developed nations.
  • Understanding the scope of healthcare utilization due to illegal drug use is crucial for public health planning.

Purpose of the Study:

  • To quantify diagnoses, hospitalizations, and treatment days attributed to illegal drug use in Canada for the year 2002.
  • To assess the trend in drug-attributable healthcare burden compared to 1992.

Main Methods:

  • Data on diagnoses and hospital days were sourced from the Canadian Institute for Health Information (CIHI).
  • Information on specialized treatment admissions and days was obtained from provincial officials and program coordinators.
  • Drug-attributable fractions (DAFs) were estimated from published literature, excluding specific conditions like neonatal drug effects and suicide.

Main Results:

  • In 2002, Canada recorded 61,026 illegal drug-related diagnoses in acute care, 1,517 psychiatric hospitalizations, and 139,773 specialized treatment admissions.
  • Mental and behavioral disorders due to psychoactive substance use were primary drivers in acute care, while drug psychoses led in psychiatric hospitalizations.
  • Total drug-attributable days reached 352,121 in acute care, 31,508 in psychiatric hospitals, and 2,851,829 in specialized treatment.
  • A significant increase in drug-attributable days was observed, particularly in acute care hospitals, rising 9.6-fold since 1992.

Conclusions:

  • Illegal drug use represents a substantial contributor to the overall morbidity burden in Canada.
  • The findings highlight a concerning increase in healthcare utilization linked to drug use over a decade.
  • A combination of prevention and harm reduction strategies is recommended to mitigate the public health impact of drug use.